A previous study provided evidence of an inflammatory immune signature in the early recovery stage (ERS) of COVID-19, suggesting COVID-19 patients are still vulnerable after hospital discharge with both CD4+, CD8+ T cells, and naïve B cells decreased remarkably with highly expressed levels of inflammatory genes (19). The gene discussed is CD8A; the disease is COVID-19.